Michael D. Chan

2papers

2 Papers

IVOct 7, 2021
A transformer-based deep learning approach for classifying brain metastases into primary organ sites using clinical whole brain MRI

Qing Lyu, Sanjeev V. Namjoshi, Emory McTyre et al.

Treatment decisions for brain metastatic disease rely on knowledge of the primary organ site, and currently made with biopsy and histology. Here we develop a novel deep learning approach for accurate non-invasive digital histology with whole-brain MRI data. Our IRB-approved single-site retrospective study was comprised of patients (n=1,399) referred for MRI treatment-planning and gamma knife radiosurgery over 21 years. Contrast-enhanced T1-weighted and T2-weighted Fluid-Attenuated Inversion Recovery brain MRI exams (n=1,582) were preprocessed and input to the proposed deep learning workflow for tumor segmentation, modality transfer, and primary site classification into one of five classes. Ten-fold cross-validation generated overall AUC of 0.878 (95%CI:0.873,0.883), lung class AUC of 0.889 (95%CI:0.883,0.895), breast class AUC of 0.873 (95%CI:0.860,0.886), melanoma class AUC of 0.852 (95%CI:0.842,0.862), renal class AUC of 0.830 (95%CI:0.809,0.851), and other class AUC of 0.822 (95%CI:0.805,0.839). These data establish that whole-brain imaging features are discriminative to allow accurate diagnosis of the primary organ site of malignancy. Our end-to-end deep radiomic approach has great potential for classifying metastatic tumor types from whole-brain MRI images. Further refinement may offer an invaluable clinical tool to expedite primary cancer site identification for precision treatment and improved outcomes.

CVFeb 16, 2019
DC-AL GAN: Pseudoprogression and True Tumor Progression of Glioblastoma Multiform Image Classification Based on DCGAN and AlexNet

Meiyu Li, Hailiang Tang, Michael D. Chan et al.

Pseudoprogression (PsP) occurs in 20-30% of patients with glioblastoma multiforme (GBM) after receiving the standard treatment. In the course of post-treatment magnetic resonance imaging (MRI), PsP exhibits similarities in shape and intensity to the true tumor progression (TTP) of GBM. So, these similarities pose challenges on the differentiation of these types of progression and hence the selection of the appropriate clinical treatment strategy. In this paper, we introduce DC-AL GAN, a novel feature learning method based on deep convolutional generative adversarial network (DCGAN) and AlexNet, to discriminate between PsP and TTP in MRI images. Due to the adversarial relationship between the generator and the discriminator of DCGAN, high-level discriminative features of PsP and TTP can be derived for the discriminator with AlexNet. Also, a feature fusion scheme is used to combine higher-layer features with lower-layer information, leading to more powerful features that are used for effectively discriminating between PsP and TTP. The experimental results show that DC-AL GAN achieves desirable PsP and TTP classification performance that is superior to other state-of-the-art methods.